<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-662
Date of Submission: 2025-06-30

This report was submitted by a Other Healthcare Professional from Miller, Gallegos and Young Medical Center concerning patient ANON-PX-9420. The subject is an adult male with a significant medical history including type 2 diabetes, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Intramuscular route at a dosage of 376mg, initiated on 2025-05-24 for Neuropathic pain and discontinued on 2025-06-17; Atorvastatin (Statin) administered via the Oral route at a dosage of 55mg, initiated on 2025-05-24 for Hypercholesterolemia and discontinued on 2025-06-17.

On approximately 2025-06-16, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Stevens-Johnson syndrome, Headache. The Hepatotoxicity was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Headache was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed miss and advised rather. The current patient status regarding this symptom is 'Not Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2025-662
report_date: '2025-06-30'
patient_details:
  patient_id: ANON-PX-9420
  gender: Male
  relevant_history:
  - type 2 diabetes
  - migraines
suspected_drugs:
- drug_name: Gabapentin
  dosage: 376mg
  route_of_administration: Intramuscular
  start_date: '2025-05-24'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
  end_date: '2025-06-17'
- drug_name: Atorvastatin
  dosage: 55mg
  route_of_administration: Oral
  start_date: '2025-05-24'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
  end_date: '2025-06-17'
adverse_reactions:
- symptom_name: Hepatotoxicity
  onset_date: '2025-06-16'
  severity: Moderate
  outcome: Unknown
  intervention_required: false
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2025-06-16'
  severity: Mild
  outcome: Unknown
  intervention_required: true
- symptom_name: Headache
  onset_date: '2025-06-16'
  severity: Severe
  outcome: Not Recovered
  intervention_required: true
  intervention_details: Prescribed miss and advised rather.
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive rechallenge
reporting_facility: Miller, Gallegos and Young Medical Center
reporter_type: Other Healthcare Professional
